

PRESS RELEASE

20 March 2026 11:00:00 CET



THIS ANNOUNCEMENT SHOULD NOT BE DISTRIBUTED, WHETHER DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, CANADA, JAPAN, NEW ZEALAND, SOUTH AFRICA OR THE UNITED STATES OF AMERICA. THIS ANNOUNCEMENT SHOULD ALSO NOT BE DISTRIBUTED IN OR INTO ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION REQUIRES ANY OTHER DOCUMENTATION, REGISTRATION, OR MEASURES BEYOND WHAT IS GOVERNED BY SWEDISH LAW.

The merger between Flerie and Lipum has been completed

The Swedish Companies Registration Office (*Sw. Bolagsverket*) has today registered the merger between Flerie AB (publ) ("Flerie") and Lipum AB (publ) ("Lipum"). The merger between Flerie and Lipum is thus completed.

With the registration, the merger has obtained final legal effect, and all assets and liabilities of Lipum have been transferred to Flerie. The merged company retains the name Flerie AB (publ) and will continue to be headquartered in Stockholm. In connection with the registration, Lipum's operations have been transferred to a new subsidiary of Flerie's wholly-owned subsidiary, Flerie Invest AB.

In conjunction with the registration of the merger, the Swedish Companies Registration Office has today registered the set-off issue, which was resolved by the Extraordinary General Meeting on 29 December 2025, of 3,039,741 new shares in Lipum. Through the issue, Lipum's share capital increased by SEK 759,935.25 and the number of shares increased by 3,039,741 shares to 24,252,179 shares.

The shareholders listed in Lipum's share register as of the record date 20 March 2026 will receive merger consideration. For every 2.4421 shares held in Lipum, shareholders will receive one (1) newly issued ordinary share in Flerie. No actions will be required from Lipum's shareholders in order to receive the merger consideration. Shares in Lipum owned by Flerie Invest AB will not entitle the holder to any merger consideration.

Lipum's shareholders are expected to receive these new shares, i.e. the merger consideration, on or about 24 March 2026. Trading in Flerie's shares will continue as usual and will not be affected by the merger process.

For more information, please visit www.flerie.com.

Important Information

In the information below, "this press release" refers to this document, its content or part thereof, oral presentations, question papers and written or oral material discussed or distributed in connection therewith. This press release is not a notice to attend an extraordinary general meeting or a merger document. This press release is also not an offer to sell, or a solicitation or invitation to submit an offer to buy, acquire or subscribe for, securities, or an incentive to make any investment, and there will be no sale of securities in jurisdictions where such an offer, request or sale would be prohibited without registration or qualification under such jurisdiction's securities law. Decisions regarding the proposed legal merger between Flerie and Lipum shall be made solely on the basis of

PRESS RELEASE

20 March 2026 11:00:00 CET



information stated in the actual notices to attend Flerie's and Lipum's extraordinary general meetings, and the merger document relating to the merger, and to independent analyses of the information therein. You should read the merger document, which has been made available prior to the extraordinary general meetings that decided on the issues set forth herein, to obtain more complete information on the merger. You should also do an independent analysis of the information contained therein and the merger document before making an investment decision.

This press release contains forward-looking information. Forward-looking information is inherently associated with known and unknown risks, uncertainties, assumptions and other factors, as it relates to circumstances and depends on circumstances that occur in the future, whether within or outside the respective Companies or the merged company's control. Such factors may cause actual results, performance and actual development to deviate significantly from what is expressed or implied in the forward-looking information. Although each company's management believes that their expectations stated in the forward-looking information are reasonable based on such information that is available to them, no guarantee is given that such forward-looking information will prove to be accurate. Undue weight should not be given to forward-looking information. The forward-looking information applies only to the day of this press release and neither Flerie nor Lipum undertake any obligation to update the forward-looking information beyond what is required pursuant to applicable law. Flerie's and Lipum's past performance does not guarantee, and does not represent, the future performance of the merged company. Furthermore, Flerie, Lipum and their respective subsidiaries, senior executives, employees and agents undertake no obligation to review, update or confirm expectations or estimates, or revise forward-looking information to reflect events that occur, or circumstances that arise, in relation to the content of the press release.

Contacts

Ola Sandborgh, CEO

ola.sandborgh@lipum.se

+46 72 218 80 21

Web: www.lipum.se**About Us**

Lipum AB (publ) is a clinical stage biopharmaceutical company specialized in discovery and development of a novel treatment for chronic inflammatory diseases. The lead candidate SOL-116 is a humanized antibody designed to provide efficacious therapy by blocking a previously overlooked target molecule of the immune system (BSSL). SOL-116 is in clinical phase with a successfully completed Phase 1 study. Together with strong preclinical data, we have a solid foundation for continued development in the treatment of rheumatoid arthritis. Lipum also explores other inflammatory diseases with a high unmet medical need. The company is based in Umeå, an excellent life science cluster in Sweden. Lipum's unique approach has attracted international attention, including a major European Commission Horizon 2020 grant. The company's share (LIPUM) is traded on the Nasdaq First North Growth Market. Certified Adviser is G&W Fondkommission.

PRESS RELEASE

20 March 2026 11:00:00 CET



Attachments

[The merger between Flerie and Lipum has been completed](#)